Immunome, Inc.
IMNMHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframePart of the healthcare sector, Immunome, Inc. (IMNM) is listed under Biotechnology. At a $2.55B market cap, Immunome, Inc. ranks as a mid-cap company within healthcare. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Market Cap
$2.55B
Beta
2.12
P/E (TTM)
—
P/E (Fwd)
-10.88
EPS (TTM)
$-2.44
EPS (Fwd)
$-2.07
ROE
-50.1%
ROA
-29.7%
Cash
$582.7M
Total Debt
$3.7M
Free CF
-$139.3M
52W Change
157.3%
Annual Financials
Cash vs Debt
Immunome, Inc. holds $582.7M in cash against $3.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$139.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -50.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Immunome, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Immunome, Inc. and its sector.